Comments

Jazz Pharmaceuticals

Q: What sector and industry does Jazz Pharmaceuticals (JAZZ) operate in?

Jazz Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

JAZZNASDAQ

Jazz Pharmaceuticals (JAZZ) Forecast

News Earnings Jazz Pharmaceuticals (JAZZ) Options Guidance Dividends Analyst Ratings Insider Trades Government Trades Short Interest

Overview Rating

Good

Technicals Analysis

100

0100

Financials Analysis

0100

Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Quotes, Forecast and News Summary

Jazz Pharmaceuticals Stock (NASDAQ: JAZZ) stock price, news, charts, stock research, profile.

Open	$125.35
Close	-
Volume / Avg.	70.68K / 611.28K
Day Range	$124.12 - $126.50
52 Wk Range	99.06 - 134.17
Market Cap	$7.48B
P/E Ratio	17.82
Dividend Yield	-
Exchange	NASDAQ
RSI	49
Short Interest	9.26%
Days to Cover	8.66

Recent News

CBD Drug For Tuberous Sclerosis: Caregivers Continue Epidiolex Treatment Citing Seizure Reduction And Cognitive Improvements

The majority of caregivers of patients with tuberous sclerosis complex (TSC) planned to continue Epidiolex treatment, citing benefits like reduced seizure frequency and improvements in cognition and communication. That's according to data from the BECOME-TSC (BEhavior, COgnition, and More with Epidiolex) caregiver survey, revealed by Jazz Pharmaceuticals plc (NASDAQ: JAZZ). New data on Epidiolex is being presented at the American Epilepsy Society (AES) 2024 Annual Meeting, being held December 6-10 in Los Angeles, California via nine company-sponsored posters.Epidiolex is the only FDA-approved prescription CBD treatment for severe forms of epilepsy. It was developed and produced by GW Pharmaceuticals, which was acquired by Jazz Pharmaceuticals in 2021.

Jelena Martinovic

Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says

Axsome's AXS-12 met Phase 3 trial goals, cutting cataplexy attacks by 77% over six months and improving cognition with a favorable safety profile.

Vandana Singh

FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For Zymework

Jazz Pharmaceuticals' Ziihera receives FDA accelerated approval for HER2-positive BTC. Phase 3 trial ongoing; Zymeworks secures $25 million milestone.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Sep

Oct

Nov

Dec

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.8

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	$125.35
Close	-
Volume / Avg.	70.68K / 611.28K
Day Range	$124.12 - $126.50
52 Wk Range	99.06 - 134.17
Market Cap	$7.48B
P/E Ratio	17.82
Dividend Yield	-
Exchange	NASDAQ
RSI	49
Short Interest	9.26%
Days to Cover	8.66

Compare

EPS better than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS better than industry

FAQ

How do I buy Jazz Pharmaceuticals (JAZZ) stock?

You can purchase shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) through any online brokerage.

View our list of the best stock brokerages

Who are Jazz Pharmaceuticals (JAZZ) competitors?

Other companies in Jazz Pharmaceuticals’s space includes: Novo Nordisk (NYSE:NVO), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Verona Pharma (NASDAQ:VRNA) and Novartis (NYSE:NVS).

What is the forecast, or price target, for Jazz Pharmaceuticals (JAZZ) stock?

Jazz Pharmaceuticals has a consensus price target of $180.26.

What is the current price for Jazz Pharmaceuticals (JAZZ)?

The stock price for Jazz Pharmaceuticals (NASDAQ: JAZZ) is $123.77 last updated December 27, 2024 at 12:16 PM EST.

Does Jazz Pharmaceuticals (JAZZ) pay a dividend?

There are no upcoming dividends for Jazz Pharmaceuticals.

When is Jazz Pharmaceuticals (NASDAQ:JAZZ) reporting earnings?

Jazz Pharmaceuticals’s Q4 earnings are confirmed for Wednesday, February 26, 2025.

Is Jazz Pharmaceuticals (JAZZ) going to split?

There is no upcoming split for Jazz Pharmaceuticals.

What sector and industry does Jazz Pharmaceuticals (JAZZ) operate in?

Jazz Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.